FDA Approved: SOGROYA — Supplemental Application (Novo Nordisk)

View source ↗

Summary

The FDA approved a supplemental application for Sogroya (somapacitan) from Novo Nordisk, updating its labeling for use in growth hormone deficiency.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency

Drugs mentioned

• Sogroya (somapacitan)

Snippet

SUPPL AP for SOGROYA (SOMAPACITAN-BECO)